435 related articles for article (PubMed ID: 8595627)
1. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M
Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
[TBL] [Abstract][Full Text] [Related]
2. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Tosaki A; Szerdahelyi P; Engelman RM; Das DK
J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
[TBL] [Abstract][Full Text] [Related]
3. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts.
Tosaki A; Engelman DT; Engelman RM; Das DK
J Pharmacol Exp Ther; 1995 Dec; 275(3):1115-23. PubMed ID: 8531071
[TBL] [Abstract][Full Text] [Related]
5. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
[TBL] [Abstract][Full Text] [Related]
6. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG
J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
[TBL] [Abstract][Full Text] [Related]
7. Adenosine triphosphate-sensitive potassium channel blocking agent ameliorates, but the opening agent aggravates, ischemia/reperfusion-induced injury. Heart function studies in nonfibrillating isolated hearts.
Tosaki A; Hellegouarch A
J Am Coll Cardiol; 1994 Feb; 23(2):487-96. PubMed ID: 8294705
[TBL] [Abstract][Full Text] [Related]
8. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury.
Lee SH; Yang MK; Lim JH; Seo HW; Yi KY; Yoo SE; Lee BH; Won HS; Lee CS; Choi WS; Shin HS
Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR
J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of nitric oxide synthesis and ischemia/reperfusion attenuate coronary vasodilator response to pinacidil in isolated rat heart.
Maczewski M; Beresewicz A
J Physiol Pharmacol; 1997 Dec; 48(4):737-49. PubMed ID: 9444621
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective effect of enantiomers of cicletanine (BN50417, BN50418) in ischaemic/reperfused isolated working rat hearts: interaction with glibenclamide.
Ferdinandy P; Szilvássy Z; Csont T; Koltai M; Droy-lefaix MT
Pharmacol Res; 1999 Mar; 39(3):225-31. PubMed ID: 10094849
[TBL] [Abstract][Full Text] [Related]
12. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
Grover GJ; D'Alonzo AJ; Sleph PG; Dzwonczyk S; Hess TA; Darbenzio RB
J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522
[TBL] [Abstract][Full Text] [Related]
13. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
Grover GJ; D'Alonzo AJ; Hess T; Sleph PG; Darbenzio RB
Cardiovasc Res; 1995 Nov; 30(5):731-8. PubMed ID: 8595620
[TBL] [Abstract][Full Text] [Related]
14. [Cardioprotective effect of cromakalim, a K+ channel opener, on isolated globally ischemic and reperfused rat hearts].
Taki H; Masuda Y; Yoshizumi M; Kitagawa T; Katoh I
Nihon Kyobu Geka Gakkai Zasshi; 1993 Mar; 41(3):438-44. PubMed ID: 8478573
[TBL] [Abstract][Full Text] [Related]
15. K(ATP)-channel activation: effects on myocardial recovery from ischaemia and role in the cardioprotective response to adenosine A1-receptor stimulation.
Ford WR; Lopaschuk GD; Schulz R; Clanachan AS
Br J Pharmacol; 1998 Jun; 124(4):639-46. PubMed ID: 9690854
[TBL] [Abstract][Full Text] [Related]
16. Effect of potassium on the action of the KATP modulators cromakalim, pinacidil, or glibenclamide on arrhythmias in isolated perfused rat heart subjected to regional ischaemia.
D'Alonzo AJ; Darbenzio RB; Hess TA; Sewter JC; Sleph PG; Grover GJ
Cardiovasc Res; 1994 Jun; 28(6):881-7. PubMed ID: 7923295
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Mg++ manipulation prevents the proarrhythmic activity of cromakalim in ischemic/reperfused diabetic hearts.
Tosaki A; Das DK
J Pharmacol Exp Ther; 1997 Jul; 282(1):309-17. PubMed ID: 9223569
[TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic effect of ischemic preconditioning during low-flow ischemia. The role of bradykinin and sarcolemmal versus mitochondrial ATP-sensitive K(+) channels.
Driamov S; Bellahcene M; Ziegler A; Barbosa V; Traub D; Butz S; Buser PT; Zaugg CE
Basic Res Cardiol; 2004 Jul; 99(4):299-308. PubMed ID: 15221348
[TBL] [Abstract][Full Text] [Related]
19. The ATP-sensitive potassium channel blocker glibenclamide (glyburide) does not abolish preconditioning in isolated ischemic rat hearts.
Grover GJ; Dzwonczyk S; Sleph PG; Sargent CA
J Pharmacol Exp Ther; 1993 May; 265(2):559-64. PubMed ID: 8496806
[TBL] [Abstract][Full Text] [Related]
20. KATP channel modulators and myocardial damages induced by ischemia-reperfusion: membrane lipids injury and arrhythmias.
Picard S; Rouet R; Duval D; Chesnay F; Gérard JL
J Mol Cell Cardiol; 1998 Dec; 30(12):2613-21. PubMed ID: 9990533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
